Idogen continues to optimize its production method prior to the start of the patient study with IDO 8
Idogen AB announces today that it has initiated new activities in order to maximize the effect of the tolerogenic cell therapy IDO 8 before the start of the first clinical study. The company has already succeeded in establishing a patentable process for the GMP-production of individually tailored treatments. Åsa Schiött, CSO of Idogen: “Recently performed analyses show a potential to optimize the levels of the substance in cell therapy that the body should learn to recognize and tolerate. This in turn would increase the possibility of an improved treatment effect to benefit the patient”.